The HDHD5 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the HDHD5 gene in the A2780 human ovarian carcinoma cell line. This heterogeneous population enables loss-of-function studies of HDHD5 without single-cell cloning, preserving polyclonal diversity relevant to ovarian cancer heterogeneity. The CRISPR/Cas9-mediated gene disruption creates a versatile model for investigating this poorly characterized putative phosphatase in oncogenic signaling and metabolic pathways.
The A2780 parental line was established from an untreated patient with ovarian endometrioid adenocarcinoma and exhibits adherent epithelial morphology and a near-diploid karyotype. Widely used in anticancer drug screening and mechanistic research, these cells retain key tumor characteristics, providing a clinically pertinent host for gene-editing approaches. A2780 has been instrumental in studying chemotherapeutic sensitivity and resistance, making it an ideal background for dissecting HDHD5-dependent processes.
HDHD5 encodes a member of the haloacid dehalogenase (HAD) superfamily and is predicted to function as a phosphatase. Its precise substrates, interacting partners, and upstream regulators remain unknown. The knockout of HDHD5 may disrupt phosphorylation-dependent signaling and metabolic regulation. Other HAD superfamily phosphatases act in nucleotide metabolism and stress responses, suggesting potential pathway intersections. This polyclonal knockout population serves as a discovery tool to identify HDHD5-mediated molecular events through phosphoproteomic and transcriptomic profiling.
Ovarian cancer progression is driven by aberrant phosphorylation and metabolic rewiring. Introducing HDHD5 knockout into A2780 cells allows systematic assessment of its contributions to proliferation, survival, and drug response. The polyclonal format captures heterogeneous phenotypes that mirror clonal tumor diversity, enhancing translational relevance. This model is valuable for investigating whether HDHD5 influences sensitivity to platinum agents or targeted therapies, and for uncovering novel roles in metabolic adaptation.
Researchers can employ Western blotting for knockout validation, phospho-specific flow cytometry or arrays for signaling analysis, cell viability and drug sensitivity assays, RNA-seq, and metabolic flux analysis. These applications facilitate comprehensive functional characterization of HDHD5 in ovarian carcinoma and may identify new therapeutic targets or biomarkers. For further technical details or ordering information, please contact Ascent Research.
